# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-22-008159
Filing Date
2022-04-01
Accepted
2022-04-01 16:09:51
Documents
9
Period of Report
2022-05-24

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | sgmo_proxyx2022xdef.htm | DEF 14A | 1352334
2 | GRAPHIC | hrdiversitychartsidebyside.jpg | GRAPHIC | 85359
3 | GRAPHIC | macraesignaturea02.jpg | GRAPHIC | 28251
4 | GRAPHIC | sangamo-2021cdagraphicfact.jpg | GRAPHIC | 116239
5 | GRAPHIC | sangamo-2021cdagraphicprim.jpg | GRAPHIC | 128981
6 | GRAPHIC | sangamo-2022cdagraphiccash.jpg | GRAPHIC | 108065
7 | GRAPHIC | sangamo-2022cdagraphicceo2.jpg | GRAPHIC | 65158
8 | GRAPHIC | sgmoproxycardp1.jpg | GRAPHIC | 131766
9 | GRAPHIC | sgmoproxycardp2.jpg | GRAPHIC | 98345
| Complete submission text file | 0001628280-22-008159.txt |  | 2387968

Mailing Address 7000 MARINA BLVD BRISBANE CA 94005
Business Address 7000 MARINA BLVD BRISBANE CA 94005 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-30171 | Film No.: 22798303
SIC: 2836 Biological Products, (No Diagnostic Substances)